•Developed
a novel B-cell vaccine platform that holds potential benefits compared to
dendritic cell (DC) and CAR-T-based immunotherapies
•A
proprietary activating agent is used to activate and expand B cells ex vivo
prior to loading with antigen and adjuvant
•Platform
has demonstrated the ability to elicit an immune response to numerous distinct
antigens. The platform is amenable to a broad range of antigens that are tumor
specific, pathogen-related and/or neoantigens
•Accompanied
by a robust multi-species preclinical data package
•Robust
efficacy in animal models as a monotherapy and in combination with checkpoint
inhibitors
•Ease
of manufacturing, stability and administration relative to CAR-T and DC
therapies